B Cell Targeted Therapy in Rheumatic Disease
Author(s) -
ChangHee Suh
Publication year - 2012
Publication title -
journal of rheumatic diseases
Language(s) - English
Resource type - Journals
eISSN - 2093-940X
pISSN - 2233-4718
DOI - 10.4078/jrd.2012.19.2.67
Subject(s) - rheumatoid arthritis , immunology , medicine , b cell , autoantibody , b cell activating factor , rituximab , antigen , autoimmune disease , immune system , cd20 , systemic lupus erythematosus , disease , antibody
B cells play an important role in the pathogenesis of autoimmune disease. B cells not only produce pathogenic autoantibodies, but also present self-antigens to T cells and provide costimulatory signals for self-reactiveT cells. Recently, biologics have been tried in several autoimmune diseases as immune modulators with some promising results. Among them, several biologic agents that target B cells have led to improved patients’ outcomes and quality of life in patients with rheumatoid arthritis and systemic lupus erythematosus. These agents either deplete B cells
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom